Update on Use of Immunotherapy in Hematologic Malignancies

Update on Use of Immunotherapy in Hematologic Malignancies

Episodes

Specialty:

All

Year:

All

EP. 1: Immunotherapy in Hematologic Malignancies

June 24th 2015

EP. 2: Responses With Immunotherapy Versus Chemotherapy

June 24th 2015

EP. 3: Immunotherapy-Related Adverse Events

June 24th 2015

EP. 4: Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015

EP. 5: Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015

EP. 6: Measuring Response to Novel Therapies in ALL

June 24th 2015

EP. 7: Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015

EP. 8: Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015

EP. 9: Treatment Advancements in Lymphoma

June 24th 2015

EP. 10: PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015

EP. 11: Future Immunotherapies for Hematologic Malignancies

June 24th 2015

Trending on OncLive

CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing

Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers

Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma

Invikafusp Alfa Earns Expanded Fast Track Designation in TMB-H Solid Tumors